<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851564</url>
  </required_header>
  <id_info>
    <org_study_id>74570</org_study_id>
    <secondary_id>11/0261</secondary_id>
    <secondary_id>13392</secondary_id>
    <nct_id>NCT01851564</nct_id>
  </id_info>
  <brief_title>RCT of Stent Versus Standard Therapy in Oesophageal Variceal Haemorrhage</brief_title>
  <acronym>SOV</acronym>
  <official_title>Effective Haemostasis Using Self-expandable Covered Mesh-metal Oesophageal Stents Versus Standard Endoscopic Therapy in the Treatment of Oesophageal Variceal Haemorrhage: A Multicentre, Open, Prospective, Randomised, Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Free Hampstead NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Bristol NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mortality rates from Acute Variceal Haemorrhage remain significant and first line therapy
      may fail in 15-25% of patients. The self-expandable metal stent has been described in case
      series as having a very high efficacy at control of haemorrhage from oesophageal varices when
      used as rescue therapy. This randomised controlled trial aims to assess for any potential
      superiority of the stent over 'standard' endoscopic techniques as primary or rescue therapy
      for bleeding oesophageal varices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite improvements in recent years, mortality from variceal bleeding remains significant.
      The routine use of banding ligation, vasoactive drugs, and antibiotics has had an impact on
      survival rates such that survival rates of patients with Childs-Pugh A and B class cirrhosis
      may be as high as 90% at 30 days. However, the successful outcome of variceal bleeding is
      compromised in some patients because of initial failure to control bleeding or early
      re-bleeding, both of which have a significant impact on mortality.

      The SX-Ella Danis stent (Ella-CS, Hradec Kralove, Czech Republic) is a removable, covered,
      self-expanding mesh-metal stent (SEMS) that can be deployed in the lower oesophagus over an
      endoscopically placed guidewire without radiological screening. The stent controls bleeding
      by tamponade of varices in the lower oesophagus.

      The series reported to date suggest that the self-expandable covered stents can provide 100%
      haemostasis rates when applied for refractory oesophageal variceal bleeding. Given the
      potentially lower risks of re-bleeding and safe, easy insertion techniques the
      self-expandable covered stents may offer a superior alternative to standard endoscopic
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure to Control Bleeding</measure>
    <time_frame>7 days</time_frame>
    <description>Failure to control Bleeding (as defined by the Baveno V Criteria) or re-bleeding within 7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of Bleeding at 14 and 42 days</measure>
    <time_frame>14 and 42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Survival</measure>
    <time_frame>7, 14, 42 days and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Stent Migration</measure>
    <time_frame>7 days</time_frame>
    <description>for the duration of stent migration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for Blood products</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for Analgesia and Sedation whilst Stent in in situ</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Thoracic Pain or Dysphagia</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit and Total Hospital Stay</measure>
    <time_frame>Total Length of Intensive Care Unit and Hospital Stay (an average of 3 and 10 days respectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for additional endoscopic therapy or salvage therapy (such as TIPS)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeated presentation with variceal bleeding within 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Unexpected Serious Adverse Device Effect</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Acute Bleeding Esophageal Varices</condition>
  <arm_group>
    <arm_group_label>SEMS for primary variceal haemorrhage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of the Self-expanding mesh-metal oesophageal stent (SEMS) as primary therapy for Acute Variceal Haemorrhage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy - Primary Haemorrhage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of standard medical and endoscopic therapy for the treatment of primary variceal haemorrhage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEMS for Failure to Control Bleeding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of the self expanding mesh-metal stent for failure of standard therapy in oesophageal variceal haemorrhage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy - Failure of Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of standard medical and endoscopic therapy for failure of standard therapy in oesophageal variceal haemorrhage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Self-expanding mesh-metal oesophageal stent (SEMS)</intervention_name>
    <description>A removable stent designed for the treatment of bleeding oesophageal varices.</description>
    <arm_group_label>SEMS for primary variceal haemorrhage</arm_group_label>
    <arm_group_label>SEMS for Failure to Control Bleeding</arm_group_label>
    <other_name>DANIS Stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Standard Medical and Endoscopic Therapy</description>
    <arm_group_label>Standard Therapy - Primary Haemorrhage</arm_group_label>
    <arm_group_label>Standard Therapy - Failure of Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Arm 1: Participants with Child-Pugh grade B or C cirrhosis with variceal haemorrhage,
             where the bleeding is from a site which would ordinarily be treated with band ligation
             . The diagnosis of cirrhosis may be proven by previous histology or suspected using
             clinical, radiological and biochemical data.

          -  Arm 2: Participants with Child-Pugh grade A, B or C cirrhosis who present with failure
             to control bleeding within 5 days of an initial attempt at standard endoscopic therapy
             of acute haemorrhage from a site which would ordinarily be treated with band ligation.

        Exclusion Criteria:

          -  &lt; 18 Years of age

          -  Child-Pugh grade A cirrhosis (for Arm 1 only)

          -  Varices which would not be treated with band ligation as standard therapy

          -  Non-cirrhotic portal hypertension

          -  Malignancy of the oesophagus, stomach or upper respiratory tract

          -  Oesophageal stenosis which prohibits endoscopy

          -  Recent oesophageal surgery

          -  A large hiatus hernia which prevents stent placement

          -  Known hepatocellular carcinoma considered to be incurable (according to Milan
             Criteria)

          -  Patients in the terminal phases of hepatological or other disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James O'Beirne, MBBS FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free London NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>United Bristol Hospitals NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004 Sep;40(3):652-9.</citation>
    <PMID>15349904</PMID>
  </reference>
  <reference>
    <citation>Burroughs AK, Triantos CK, O'Beirne J, Patch D. Predictors of early rebleeding and mortality after acute variceal hemorrhage in patients with cirrhosis. Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):72-3. doi: 10.1038/ncpgasthep1336. Epub 2008 Dec 17.</citation>
    <PMID>19092789</PMID>
  </reference>
  <reference>
    <citation>Ben-Ari Z, Cardin F, McCormick AP, Wannamethee G, Burroughs AK. A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol. 1999 Sep;31(3):443-50. Erratum in: J Hepatol 2001 Apr;34(4):640.</citation>
    <PMID>10488702</PMID>
  </reference>
  <reference>
    <citation>D'Amico G, De Franchis R; Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003 Sep;38(3):599-612.</citation>
    <PMID>12939586</PMID>
  </reference>
  <reference>
    <citation>de Franchis R; Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010 Oct;53(4):762-8. doi: 10.1016/j.jhep.2010.06.004. Epub 2010 Jun 27.</citation>
    <PMID>20638742</PMID>
  </reference>
  <reference>
    <citation>Hubmann R, Bodlaj G, Czompo M, Benkö L, Pichler P, Al-Kathib S, Kiblböck P, Shamyieh A, Biesenbach G. The use of self-expanding metal stents to treat acute esophageal variceal bleeding. Endoscopy. 2006 Sep;38(9):896-901.</citation>
    <PMID>16981106</PMID>
  </reference>
  <reference>
    <citation>Zehetner J, Shamiyeh A, Wayand W, Hubmann R. Results of a new method to stop acute bleeding from esophageal varices: implantation of a self-expanding stent. Surg Endosc. 2008 Oct;22(10):2149-52. doi: 10.1007/s00464-008-0009-7. Epub 2008 Jul 12.</citation>
    <PMID>18622540</PMID>
  </reference>
  <reference>
    <citation>Wright G, Lewis H, Hogan B, Burroughs A, Patch D, O'Beirne J. A self-expanding metal stent for complicated variceal hemorrhage: experience at a single center. Gastrointest Endosc. 2010 Jan;71(1):71-8. doi: 10.1016/j.gie.2009.07.028. Epub 2009 Oct 30.</citation>
    <PMID>19879564</PMID>
  </reference>
  <reference>
    <citation>Sarin SK, Kumar A. Gastric varices: profile, classification, and management. Am J Gastroenterol. 1989 Oct;84(10):1244-9. Review.</citation>
    <PMID>2679046</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):922-38. Erratum in: Hepatology. 2007 Dec;46(6):2052.</citation>
    <PMID>17879356</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Haemorrhage</keyword>
  <keyword>Varices</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

